Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Neurogene (NGNE) over the last 4 years, with Sep 2025 value amounting to $800,000.

  • Neurogene's Depreciation & Amortization (CF) changed negligibly% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 3.98%. This contributed to the annual value of $3.2 million for FY2024, which is 3.03% down from last year.
  • Per Neurogene's latest filing, its Depreciation & Amortization (CF) stood at $800,000 for Q3 2025, which was down 0.00% from $800,000 recorded in Q2 2025.
  • Neurogene's Depreciation & Amortization (CF)'s 5-year high stood at $855,000 during Q4 2023, with a 5-year trough of $749,000 in Q1 2025.
  • In the last 3 years, Neurogene's Depreciation & Amortization (CF) had a median value of $800,000 in 2025 and averaged $801,818.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first grew by 0.25% in 2024, then fell by 7.99% in 2025.
  • Over the past 3 years, Neurogene's Depreciation & Amortization (CF) (Quarterly) stood at $855,000 in 2023, then fell by 7.60% to $790,000 in 2024, then remained steady at $800,000 in 2025.
  • Its last three reported values are $800,000 in Q3 2025, $800,000 for Q2 2025, and $749,000 during Q1 2025.